En definitiva, tanto por los efectos secundarios asociados como por el desabastecimiento que puede causar que los pacientes diabticos no puedan adquirir su medicacin, su uso indiscriminado sin padecer diabetes u obesidad es totalmente irresponsable
"These data are the first to show the combined use of tirzepatide and menopause hormone therapy significantly increases treatment effectiveness in postmenopausal women," said Regina Castaneda, M.D., research fellow for the Division of Endocrinology at the Mayo Clinic in Jacksonville, Fla
I have been blamed and shamed, and I blamed and shamed myself. She talked about finally ridding herself of this immense burden: her shame
The SURMOUNT-4 trial showed that 82.5% of people who stopped regained at least 25% of their lost weight within a year
#CaringforLife #CiplaAt90 To view or add a comment, sign in Cipla launches Yurpeak (tirzepatide), a one-weekly injectable therapy for managing obesity and type 2 diabetes mellitus (T2DM) two of the countrys most pressing health challenges